PCM
CTSO icon

Prelude Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Prelude Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,000
Closed -$16K – 1403
2020
Q3 		$16K Buy
+2,000
New +$18K ﹤0.01% 1370
2019
Q1 		– Sell
-136
Closed -$1K – 1813
2018
Q4 		$1K Sell
136
-1,320
-91% -$13.1K ﹤0.01% 1709
2018
Q3 		$19K Sell
1,456
-2,496
-63% -$31.3K ﹤0.01% 1314
2018
Q2 		$45K Buy
3,952
+1,831
+86% +$17.3K ﹤0.01% 1143
2018
Q1 		$15K Buy
+2,121
New +$16K ﹤0.01% 1296

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's CTSO Position: Q4 2020 in Review

Prelude Capital Management sold out of Cytosorbents Corp (CTSO) in Q4 2020, closing a stake of 2,000 shares — an estimated $16K sold.

Prelude Capital Management first reported a position in CTSO in Q1 2018 and held it in 5 quarters. The position peaked at $45K in Q2 2018. 94 funds tracked by Wall St. Rank hold CTSO as of Q4 2020.

  • Prelude Capital Management reported no remaining Cytosorbents Corp position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 2,000 Cytosorbents Corp shares in Q4 2020, an estimated $16K.
  • Prelude Capital Management first reported a position in Cytosorbents Corp in Q1 2018 and held it in 5 quarters.
  • Prelude Capital Management's Cytosorbents Corp position peaked at $45K in Q2 2018.
  • 94 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.